Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
$150.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Announces Exclusive Option To Acquire Adynxx, Inc


Monday, 25 Feb 2013 08:30am EST 

Cubist Pharmaceuticals Inc and Adynxx, Inc. announced that they have entered into an option agreement under which Cubist has the exclusive right to acquire Adynxx following the data readout of Adynxx's Phase 2 trial for lead product candidate, AYX1. Pursuant to the agreement, Cubist will pay Adynxx to secure the option right. Cubist will fund the consideration with cash on hand. If Cubist exercises right to acquire Adynxx, Cubist will make additional payments to the Adynxx stockholders. Terms of the transaction were not disclosed. 

Company Quote

62.65
0.07 +0.11%
24 Jul 2014